United Therapeutics Corp.

UTHR-Q

NASDAQ:UTHR

105.69
0.98 (0.92%)
United Therapeutics is a biotechnology company. It is listed on the NASDAQ. Its headquarters are located in Silver Spring, Maryland, with additional facilities in Research Triangle Park, North Carolina; ...
More at Wikipedia

Analysis and Opinions about UTHR-Q

Signal
Opinion
Expert
COMMENT
COMMENT
November 30, 2016

United Therapeutic (UTHR-Q) or Allergan (AGN-N)? This is a tough one because they are 2 very different companies. Allergan is a much larger company and more broadly-based, however, this one is a very fine company. Its primary drug therapy is dealing with pulmonary disease. The risk of owning this is that one drug represents a high percentage of their total revenue.

Show full opinionHide full opinion

United Therapeutic (UTHR-Q) or Allergan (AGN-N)? This is a tough one because they are 2 very different companies. Allergan is a much larger company and more broadly-based, however, this one is a very fine company. Its primary drug therapy is dealing with pulmonary disease. The risk of owning this is that one drug represents a high percentage of their total revenue.

COMMENT
COMMENT
November 22, 2016

A good company. ROC has been improving, and has been very high. Back in 2008, it had a 4% ROC. Including the trailing 4 quarters, he now shows a 35% ROC, so he knows the company is doing everything right. Remember that when you have that high return, it can turn over really fast, but for now it is good.

Show full opinionHide full opinion

A good company. ROC has been improving, and has been very high. Back in 2008, it had a 4% ROC. Including the trailing 4 quarters, he now shows a 35% ROC, so he knows the company is doing everything right. Remember that when you have that high return, it can turn over really fast, but for now it is good.

PAST TOP PICK
PAST TOP PICK
January 2, 2014

(A Top Pick Dec 19/12. Up 115.38%.) Involved in a very specialized area, pulmonary arterial hypertension, which is high blood pressure in the lungs. The big spike in the stock price came as a result of FDA approval of an oral application for one of their drugs. They are quickly establishing themselves as the “go to” drug maker in this critical area where a lot of people are at risk.

Show full opinionHide full opinion

(A Top Pick Dec 19/12. Up 115.38%.) Involved in a very specialized area, pulmonary arterial hypertension, which is high blood pressure in the lungs. The big spike in the stock price came as a result of FDA approval of an oral application for one of their drugs. They are quickly establishing themselves as the “go to” drug maker in this critical area where a lot of people are at risk.

PAST TOP PICK
PAST TOP PICK
December 3, 2013

(A Top Pick Dec 19/12. Up 81.38%.) Bio-pharmas are interesting because they have got a pipeline that is very exciting with new drugs coming on that are biology-based as opposed to chemical-based. Have always been extremely expensive, but this one isn’t. Trading at about 14-15 times next years earnings. There has to be a continuation of the acceptance of the existing product, but what he is really hoping for is an expansion of their product offering. They have 3 main drugs that they get most of their revenues off of. He’d like to see that at 6 or 12.

Show full opinionHide full opinion

(A Top Pick Dec 19/12. Up 81.38%.) Bio-pharmas are interesting because they have got a pipeline that is very exciting with new drugs coming on that are biology-based as opposed to chemical-based. Have always been extremely expensive, but this one isn’t. Trading at about 14-15 times next years earnings. There has to be a continuation of the acceptance of the existing product, but what he is really hoping for is an expansion of their product offering. They have 3 main drugs that they get most of their revenues off of. He’d like to see that at 6 or 12.

TOP PICK
TOP PICK
December 19, 2012

It is going to be news driven. In October one of their drugs was turned down by the FDA. The more drugs they have in their pipeline the less you will see of this. Growing well. Thinks it is good value. 10 times earnings.

Show full opinionHide full opinion

It is going to be news driven. In October one of their drugs was turned down by the FDA. The more drugs they have in their pipeline the less you will see of this. Growing well. Thinks it is good value. 10 times earnings.

Showing 1 to 5 of 5 entries
  • «
  • 1
  • »

United Therapeutics Corp.(UTHR-Q) Rating

Ranking : 1 out of 5

Bullish - Buy Signals / Votes : 0

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 0

Stockchase rating for United Therapeutics Corp. is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

United Therapeutics Corp.(UTHR-Q) Frequently Asked Questions

What is United Therapeutics Corp. stock symbol?

United Therapeutics Corp. is a American stock, trading under the symbol UTHR-Q on the NASDAQ (UTHR). It is usually referred to as NASDAQ:UTHR or UTHR-Q

Is United Therapeutics Corp. a buy or a sell?

In the last year, there was no coverage of United Therapeutics Corp. published on Stockchase.

Is United Therapeutics Corp. a good investment or a top pick?

United Therapeutics Corp. was recommended as a Top Pick by Gordon Reid on 2016-11-30. Read the latest stock experts ratings for United Therapeutics Corp..

Why is United Therapeutics Corp. stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is United Therapeutics Corp. worth watching?

In the last year, there was no coverage of United Therapeutics Corp. published on Stockchase.

What is United Therapeutics Corp. stock price?

On 2020-09-18, United Therapeutics Corp. (UTHR-Q) stock closed at a price of $105.69.